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Stroke and recurrent haemorrhage associated with 
antithrombotic treatment after gastrointestinal bleeding 
in patients with atrial fibrillation: nationwide cohort study
Laila Staerk,1,2 Gregory Y H Lip,2 Jonas B Olesen,1 Emil L Fosbøl,3 Jannik L Pallisgaard,1  
Anders N Bonde,1 Anna Gundlund,1 Tommi B Lindhardt,1 Morten L Hansen,3 Christian  
Torp-Pedersen,4 Gunnar H Gislason1,5,6,7 
ABSTRACT
Study queStion
What are the risks of all cause mortality, 
thromboembolism, major bleeding, and recurrent 
gastrointestinal bleeding associated with restarting 
antithrombotic treatment after gastrointestinal 
bleeding in patients with atrial fibrillation?
MethodS
This Danish cohort study (1996-2012) included all 
patients with atrial fibrillation discharged from 
hospital after gastrointestinal bleeding while receiving 
antithrombotic treatment. Restarted treatment 
regimens were single or combined antithrombotic 
drugs with oral anticoagulation and antiplatelets. 
Follow-up started 90 days after discharge to avoid 
confounding from use of previously prescribed drugs 
on discharge. Risks of all cause mortality, 
thromboembolism, major bleeding, and recurrent 
gastrointestinal bleeding were estimated with 
competing risks models and time dependent multiple 
Cox regression models.
Study anSwer and liMitationS
4602 patients (mean age 78 years) were included. 
Within two years, 39.9% (95% confidence interval 
38.4% to 41.3%, n=1745) of the patients had died, 
12.0% (11.0% to 13.0%, n=526) had experienced 
thromboembolism, 17.7% (16.5% to 18.8%, n=788) 
major bleeding, and 12.1% (11.1% to 13.1%, n=546) 
recurrent gastrointestinal bleeding. 27.1% (n=924) of 
patients did not resume antithrombotic treatment. 
Compared with non-resumption of treatment, a 
reduced risk of all cause mortality was found in 
association with restart of oral anticoagulation 
(hazard ratio 0.39, 95% confidence interval 0.34 
to 0.46), an antiplatelet agent (0.76, 0.68 to 0.86), 
and oral anticoagulation plus an antiplatelet 
agent (0.41, 0.32 to 0.52), and a  reduced risk of 
thromboembolism was found in association with 
restart of oral anticoagulation (0.41, 0.31 to 0.54), 
an antiplatelet agent (0.76, 0.61 to 0.95), and oral 
anticoagulation plus an antiplatelet agent (0.54, 
0.36 to 0.82). Restarting oral anticoagulation alone 
was the only regimen with an increased risk of major 
bleeding (1.37, 1.06 to 1.77) compared with non-
resumption of treatment; however, the difference in 
risk of recurrent gastrointestinal bleeding was not 
significant between patients who restarted an 
antithrombotic treatment regimen and those who 
did not resume treatment. 
what thiS Study addS
Among patients with atrial fibrillation who 
experience gastrointestinal bleeding while receiving 
antithrombotic treatment; subsequent restart of 
oral anticoagulation alone was associated with 
better outcomes for all cause mortality and 
thromboembolism compared with patients who did 
not resume treatment. This was despite an 
increased longitudinal associated risk of bleeding.
Funding, CoMpeting intereStS, data Sharing
 This study was supported by a grant from Boehringer-
Ingelheim. Competing interests are available in the full 
paper on bmj.com. The authors have no additional 
data to share.
Introduction
Patients with non-valvular atrial fibrillation and risk 
factors for thromboembolism require anticoagulant 
treatment to reduce the risk of stroke.1 2  The major 
complication with anticoagulant treatment is the 
increased risk of bleeding,3  particularly gastrointesti-
nal bleeding.4-6
After patients have experienced gastrointestinal 
bleeding during antithrombotic treatment, their clini-
cians face the clinical dilemma of whether to restart 
treatment or not. Moreover, there are several treatment 
regimens for clinicians to choose from: single or com-
bined treatment with a vitamin K antagonist, a non-vi-
tamin K antagonist oral anticoagulant, aspirin 
(acetylsalicylic acid), and an adenosine diphosphate 
receptor antagonist (clopidogrel, prasugrel, or ticagre-
lor).2 7 8  It is important to clarify how clinicians should 
treat patients with atrial fibrillation after antithrom-
botic related gastrointestinal bleeding; however, data 
WhAT IS AlReAdy knoWn on ThIS TopIC
The gastrointestinal tract is the most common site of bleeding due to oral 
anticoagulant treatment among patients with atrial fibrillation
Data on whether to restart antithrombotic treatment or withhold treatment after 
gastrointestinal bleeding are scarce
WhAT ThIS STudy AddS
In this study over a third of patients with atrial fibrillation discharged after 
gastrointestinal bleeding while taking antithrombotics died within two years
Under a third did not resume antithrombotics after gastrointestinal bleeding
Restarting single treatment with oral anticoagulation was associated with the 
lowest risk of all cause mortality and thromboembolism, and a relative safe use 
regarding risk of recurrent bleeding, compared with non-resumption of 
antithrombotic treatment
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on this are scarce, and no randomised controlled trial 
has been performed to elucidate the clinical dilemma 
regarding risk of stroke versus risk of bleeding in these 
patients.5 9 10
In a nationwide cohort study, we examined the risk of 
all cause mortality and admission to hospital or deaths 
due to thromboembolism, major bleeding, or recurrent 
gastrointestinal bleeding associated with restarting 
antithrombotic treatment after a gastrointestinal bleed 
in patients with atrial fibrillation.
Methods
In Denmark, all residents receive a unique and per-
manent civil registration number at birth or immigra-
tion that allows linkage between nationwide 
registries at an individual level. We obtained data 
from the following three sources. Firstly, the Danish 
national patient registry, which holds information on 
all hospital admissions since 1978 and at discharge; 
each hospital admission is coded with one primary 
and, if appropriate, one or more secondary diagno-
ses, in accordance with the International Classifica-
tion of Diseases, the eighth revision until 1994 and 
the 10th revision thereafter. In addition, the registry 
keeps information on all procedures and surgical 
operations since 1996 (the Nordic Medical Statistics 
Committees classification of surgical procedures).11 
Secondly, the Danish national prescription registry, 
which records all claimed drug prescriptions from 
pharmacies in Denmark since 1995.12  Finally, the 
Danish civil registration system, which contains 
information about an individual’s vital status and 
cause of death.13
Study population
We included all patients with atrial fibrillation who 
experienced gastrointestinal bleeding while receiving 
single or combined antithrombotic treatment with a 
vitamin K antagonist, dabigatran, rivaroxaban, aspirin, 
clopidogrel, prasugrel, or ticagrelor. Patients were 
included on the day of discharge from a first time 
admission to hospital owing to gastrointestinal bleed-
ing in the study period from 1 January 1996 to 31 Decem-
ber 2012. We referred to the day of admission as the 
inclusion event and the day of discharge as the inclu-
sion day.
In registries, the positive predictive value of bleeding 
related hospital admission is between 89% and 99%14 ; 
that is, among all patients with a diagnosis code of 
bleeding, 89% to 99% were actually admitted to hospi-
tal with bleeding. Moreover, the agreement with regard 
to specific bleeding site suggests that misclassification 
is rare.14
To assemble a homogeneous study population with 
atrial fibrillation and treated with antithrombotics, we 
excluded patients aged less than 30 or more than 100, 
patients with valvular heart disease, patients with total 
hip or knee replacement surgery up to eight weeks 
before the inclusion event, and patients with deep vein 
thrombosis or pulmonary embolism up to six months 
before the inclusion event.
antithrombotic treatment
To assess the resumption of antithrombotic treatment 
after discharge from hospital for gastrointestinal bleed-
ing, we defined a 90 days blanking period—that is, fol-
low-up did not start until inclusion day plus 90 days. All 
patients who died or experienced a thromboembolic 
event, major bleeding, or recurrent gastrointestinal 
bleeding in the 90 days blanking period were excluded. 
We divided the remaining patients who survived with-
out an event until baseline, into groups according to 
type of antithrombotic treatment regimen restarted in 
the blanking period. The restarted groups were single 
treatment with oral anticoagulation (vitamin K antago-
nist, dabigatran, or rivaroxaban), single treatment with 
an antiplatelet agent (aspirin or an adenosine diphos-
phate receptor antagonist (clopidogrel, prasugrel, or 
ticagrelor)), and dual or triple treatment with oral anti-
coagulation, aspirin, and an adenosine diphosphate 
receptor antagonist.
We chose a blanking period of 90 days since in Den-
mark the numbers of tablets in the largest packet size 
available for antithrombotics last for approximately 
three months. This was done to remove the uncertainty 
about whether patients initially after discharge used 
antithrombotic drugs from an old package purchased 
before the gastrointestinal bleed. We kept records on 
the day each prescription was dispensed, the package 
size, and dosage. By using this method, we calculated 
patients’ time dependent antithrombotic use during fol-
low-up, as done in previous studies.4 15 16
Concomitant medical treatment and comorbidities
To identify concomitant medical treatment at the time 
of the inclusion event, we used prescriptions filled 
from 0 to 90 days before the admission for gastrointes-
tinal bleeding. To identify concomitant medical treat-
ment at baseline, we used prescriptions filled during 
the 90 days blanking period. We determined comor-
bidities and invasive and surgical procedures from 
diagnosis and procedure codes based on validated 
methods.17-20
We assessed stroke and bleeding risks with risk 
stratification schemes according to CHADS2 (conges-
tive heart failure, hypertension, age ≥75 years, diabe-
tes mellitus, stroke or transient ischaemic attack 
(double weight)), CHA2DS2-VASc (CHADS2 with vascu-
lar disease, age 65 to 74, and female sex added and 
double weight of age ≥75 years), and HAS-BLED 
(hypertension, abnormal renal or liver function, 
stroke, previous bleeding, international normalised 
ratio (left out because data are unfilled), elderly (age 
>65 years), and drug (antiplatelet agents, non-steroi-
dal anti-inflammatory drugs) or alcohol misuse) scores 
as in previous studies.15 21 A low CHADS2 or CHA2DS2-
VASc score indicated a low risk of stroke, and a low 
HAS-BLED score indicated a low risk of bleeding. The 
predicted risk of stroke or bleeding increases when the 
scores increase. Supplementary table 1 lists all Ana-
tomical Therapeutic Chemical Classification System 
codes, diagnosis codes, and invasive procedure codes 
used in the study. 
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outcomes and follow-up
The outcomes of interest were all cause mortality or 
admission to hospital or death due to thromboembo-
lism, major bleeding, or recurrent gastrointestinal 
bleeding. We defined thromboembolism by diagnosis 
codes for ischaemic stroke, transient ischaemic attack, 
or systemic thromboembolism. Validation of the 
 ischaemic stroke diagnosis showed that among all 
patients listed with ischaemic stroke in the Danish 
national patient registry, 97% to 100% truly had isch-
aemic stroke—that is, the positive predictive value was 
97% to 100%. The positive predictive value for transient 
ischaemic attack ranges from 57.9% to 68.4%.19  Major 
bleeding was determined by diagnosis codes of intracra-
nial bleeding, or severe bleeding from the respiratory, 
gastrointestinal, or urinary tract.14  We identified recur-
rent gastrointestinal bleeding by all diagnosis codes of 
gastrointestinal bleeding.14
Follow-up of patients was until either of the out-
comes, death, five year follow-up, or 31 December 2012, 
whichever came first.
Statistical analysis
We present the inclusion day and baseline characteris-
tics as numbers and percentages or as means and stan-
dard deviations where appropriate. For categorical data 
we used χ2 tests.
To estimate the cumulative incidence of outcomes, 
taking into account the risk of death from other causes, 
we used the Aalen-Johansen method (competing 
risks).22
We used time dependent Cox proportional hazards 
models to examine the risk of events during follow-up 
for the different groups restarting antithrombotic 
 treatment, with patients not resuming antithrombotic 
treatment as reference. As the number of patients who 
restarted triple treatment was small, we excluded them 
from the analysis. We constituted the different anti-
thrombotic treatment regimens as time varying covari-
ates, which allowed patients to switch their treatment 
regimen during follow-up. The models were adjusted 
for factors in the CHA2DS2-VASc score and for treatment 
with antiplatelets during the 90 days blanking period. 
We considered a two sided significance level of less 
than 0.05 to be significant. We checked to ensure that 
the Cox models all fulfilled the proportional hazard 
assumption and linearity of continuous covariates 
(age). In addition, we explored relevant interactions 
without any clinical significant findings, including no 
sex based differences.
Data management and statistical analyses were 
performed using SAS (version 9.2 for Windows, SAS 
Institute, NC) and R (version 3.0.2 for Windows, R 
Foundation for Statistical Computing).
patient involvement
No patients were involved in setting the research ques-
tion or the outcome measures, nor were they involved 
in the design and implementation of the study. There 
are no plans to involve patients in dissemination of the 
results.
Results
index study population
Figure 1  shows the selection of the study population 
from 1 January 1996 to 31 December 2012. Overall, 4602 
Patients with atrial brillation who experienced gastrointestinal bleeding (n=7845)
Inclusion day
Patients discharged aer antithrombotic related gastrointestinal bleeding (n=4602)
Baseline
90 days aer inclusion day (n=3409)
Oral anticoagulation +
aspirin + adenosine
diphosphate receptor
antagonist (n=11)
Aspirin + adenosine
diphosphate receptor
antagonist (n=51)
Oral anticoagulation
+ antiplatelets (n=384)
Antiplatelets
(n=1314)
Oral anticoagulation
(n=725)
Non-resumption (n=924)
Triple treatmentDual treatmentSingle treatment
Excluded (n=3243):
  Age <30 or >100 years (n=6)
  Valvular disease (n=1002)
  Total hip or knee arthroplasty within ve weeks (n=127)
  Pulmonary embolism or deep vein thrombosis within six months (n=95)
  No antithrombotic treatment before gastrointestinal bleeding (n=2013)
Excluded within 90 days blanking period (n=1193):
  Thromboembolism (n=217)
  Recurrent gastrointestinal bleeding (n=371)
  Major bleeding (n=108)
  Death (n=423)
  Study period ended before follow-up started (n=74)
Fig 1 | Selection of study population. antiplatelets comprise aspirin or adenosine diphosphate receptor antagonists
doi1 02.00;76/bmj.h15876 | BMJ   2015;101h15876 | the bmj
RESEARCH
4
patients with atrial fibrillation were discharged from 
hospital after a first time gastrointestinal bleed while 
receiving antithrombotic treatment, referred to as the 
inclusion day. Table 1 presents the characteristics of 
these patients.
outcomes after index bleeding event
Figure 2 shows the cumulative incidences of outcomes 
after inclusion day accounting for competing risk of 
death. At two years the cumulative incidence of all 
cause mortality was 39.9% (95% confidence interval 
38.4% to 41.3%, n=1745), thromboembolism 12.0% 
(11.0% to 13.0%, n=526), major bleeding 17.7% (16.5% to 
18.8%, n=788), or recurrent gastrointestinal bleeding 
12.1% (11.1% to 13.1%, n=546). The incidences of all 
cause mortality, major bleeding, and recurrent gastro-
intestinal bleeding increased noticeably within the first 
month after the inclusion day, whereas the incidence of 
thromboembolism showed a regular increase over two 
years.
Baseline study population
Overall, we excluded 1193 patients in the 90 days blank-
ing period between the inclusion day and baseline 
(fig 1). The baseline study population thus comprised 
3409 patients. Table 2 shows the baseline characteris-
tics of this population.
The overall mean age of the baseline population 
was 77.9 (SD 9.3) years, and 44.6% (n=1521) of the 
patients were women. The mean CHA2DS2-VASc score 
was 3.6 (SD 1.5) and mean HAS-BLED score was 3.0 
(SD 1.0).
Antithrombotic treatment was restarted in 72.9% 
(n=2485) of the patients: single treatment with 
oral anticoagulation (21.3%, n=725), aspirin (35.5%, 
n=1212), or an adenosine diphosphate receptor 
 antagonist (3.0%, n=102); dual treatment with oral 
anticoagulation plus aspirin (10.7%, n=363), oral anti-
coagulation plus an adenosine diphosphate receptor 
antagonist (0.6%, n=21), or aspirin plus an adenosine 
diphosphate receptor antagonist (1.5%, n=51); or triple 
treatment with oral anticoagulation plus aspirin plus 
an adenosine diphosphate receptor antagonist (0.3%, 
n=11). Of 725 patients who restarted single treatment 
with oral anticoagulation, 10 patients restarted dabig-
atran and one rivaroxaban. Furthermore, 384 patients 
restarted dual treatment with oral anticoagulation 
plus an antiplatelet agent, of whom two received dab-
igatran plus an antiplatelet agent. Non-vitamin K 
antagonist oral anticoagulants were not included in 
the other baseline groups.
table 1 | Characteristics of patients with inclusion bleeding event. Values are numbers 
(percentages) unless stated otherwise
Characteristics
total population 
(n=4602)
Mean (SD) age, years 78.3 (9.3)
Women 2085 (45.3)
Mean (SD) CHADS2 score 2.1 (1.2)
Mean (SD) CHA2DS2-VASc score 3.6 (1.5)
Mean (SD) HAS-BLED score 2.6 (1.0)
Antithrombotic treatment the day before the inclusion event:
 Single: oral anticoagulation 1101 (23.9)
 Single: antiplatelets 2450 (53.3)
 Dual: oral anticoagulation+antiplatelets 893 (19.4)
 Dual: aspirin+adenosine diphosphate receptor antagonists 117 (2.5)
 Triple: oral anticoagulation+aspirin+adenosine diphosphate receptor antagonists 41 (0.9)
Concomitant drugs:
 Dipyridamole (persantin) 199 (4.3)
 Heparin 20 (0.4)
 Non-steroidal anti-inflammatory drug 1126 (24.5)
 Proton pump inhibitor 693 (15.1)
 H2 receptor antagonist 121 (2.6)
Comorbidities:
 Stroke or thromboembolism 1034 (22.5)
 Myocardial infarction 681 (14.8)
 Ischaemic heart disease 1749 (38.0)
 Peripheral arterial disease 290 (6.3)
 Vascular disease 903 (19.6)
 Heart failure 1411 (30.7)
 Hypertension 2058 (44.7)
 Diabetes 743 (16.2)
 Chronic kidney disease 304 (6.6)
 Liver failure 64 (1.4)
 Previous bleeding 635 (13.8)
 Alcohol misuse 219 (4.8)
 Gastroesophageal reflux 45 (1.0)
 Gastric or duodenal ulcer 302 (6.6)
 Gastritis 37 (0.8)
Invasive and surgical procedures:
 Gastrointestinal surgery 935 (20.3)
 Gastroscopy 1074 (23.3)
Months since inclusion day
Numbers at risk
Cu
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e
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4602
4602
4602
4602
All cause mortality
Thromboembolism
Major bleeding
Recurrent gastrointestinal bleeding
3503
3379
3168
3232
3025
2870
2684
2756
2649
2476
2303
2396
2306
2180
2010
2122
0
0.1
0.2
0.3
0.4
0.5
All cause mortality
Thromboembolism
Major bleeding
Recurrent gastrointestinal bleeding
Fig 2 | Cumulative incidences of all cause mortality, 
thromboembolism, major bleeding, or recurrent 
gastrointestinal bleeding counted from day after 
discharge from hospital for antithrombotic related 
gastrointestinal bleeding. For outcomes thromboembolism, 
major bleeding, or recurrent gastrointestinal bleeding the 
model accounts for risk of death from other causes 
(competing risks)
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Cumulative incidences
Figure 3 shows cumulative incidences for all cause mor-
tality, thromboembolism, major bleeding, or recurrent 
gastrointestinal bleeding stratified by baseline groups 
(similar to intention to treat) accounting for competing 
risk of death. The incidence of all cause mortality within 
the first five years increased significantly for non-resump-
tion and restart of single treatment with antiplatelets 
compared with the other baseline groups. The cumulative 
incidence of thromboembolism was generally lowest for 
restart of oral anticoagulation; however, this was not sig-
nificant in relation to the other baseline groups.
risk of outcomes associated with antithrombotic 
treatment after baseline
The median duration of follow-up was 2.0 years (inter-
quartile range 0.7 to 4.0 years). Table 3 presents the time 
dependent adjusted hazard ratios of outcomes with 
Years since baseline
Numbers at risk
Cu
m
ul
at
iv
e 
in
ci
de
nc
e
All cause mortality
0 1 2 3 4 5
924
725
1314
384
51
Non-resumption
Single: oral anticoagulation
Single: antiplatelets
Dual: oral anticoagulation + antiplatelets
Dual: aspirin + adenosine diphosphate receptor antagonist
666
557
964
300
38
514
457
737
227
27
382
362
550
155
25
278
278
393
111
23
200
217
291
85
18
0
0.2
0.4
0.6
0.8
1.0
Years since baseline
Cu
m
ul
at
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e 
in
ci
de
nc
e
Thromboembolism
0 1 2 3 4 5
924
725
1314
384
51
633
545
931
291
37
477
442
687
213
26
343
338
507
140
22
248
254
356
95
20
177
196
256
69
15
0
0.05
0.10
0.15
0.20
0.25
0.05
0.10
0.15
0.20
0.25
0.05
0.10
0.15
0.20
0.25
Years since baseline
Numbers at risk
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m
ul
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e 
in
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e
Major bleeding
0 1 2 3 4 5
924
725
1314
384
51
Non-resumption
Single: oral anticoagulation
Single: antiplatelets
Dual: oral anticoagulation + antiplatelets
Dual: aspirin + adenosine diphosphate receptor antagonist
628
524
925
286
36
467
418
677
205
23
346
321
489
135
21
241
242
336
92
20
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15
0
Years since baseline
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Recurrent gastrointestinal bleeding
0 1 2 3 4 5
924
725
1314
384
51
649
532
939
290
37
493
435
708
219
25
365
341
522
146
23
263
256
365
104
21
188
197
264
77
17
0
Non-resumption
Single: oral anticoagulation
Single: antiplatelets
Dual: oral anticoagulation + antiplatelets
Dual: aspirin + adenosine diphosphate receptor antagonist
Fig 3 | Cumulative incidences of all cause mortality, thromboembolism, major bleeding, or recurrent gastrointestinal 
bleeding after baseline, stratified by baseline groups. For outcomes thromboembolism, major bleeding, or recurrent 
gastrointestinal bleeding the model accounts for risk of death from other causes (competing risks). antiplatelets 
comprise aspirin or adenosine diphosphate receptor antagonists
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antithrombotic treatment during follow-up in patients 
surviving the first 90 days after  gastrointestinal 
 bleeding. The reference was non-resumption of anti-
thrombotic treatment.
Restart of single treatment with oral anticoagulation 
was associated with the lowest rate of all cause mortal-
ity (hazard ratio 0.39, 0.34 to 0.46) and thromboembo-
lism (0.41, 0.31 to 0.54). Among the different treatment 
regimens that were restarted, the risk of major bleeding 
was significantly increased only in patients who 
restarted single treatment with oral anticoagulation 
(1.37, 1.06 to 1.77); however, the risk of recurrent 
 gastrointestinal bleeding associated with any of the 
restarted groups was not significantly different from the 
reference group.
Additional analyses stratifying the study population 
at the inclusion event into three groups according to 
CHA2DS2-VASc score <2, CHA2DS2-VASc score 2 or 3, 
and CHA2DS2-VASc score >3 indicated that a gradual 
increase of the CHA2DS2-VASc score at the inclusion 
event was associated with a gradual decrease in the 
risk of all cause mortality among patients who 
restarted single treatment with oral anticoagulation. 
Moreover, a HAS-BLED score >3 at the inclusion event 
showed an increased associated risk of recurrent gas-
trointestinal bleeding in patients who restarted single 
treatment with oral anticoagulation (see supplemen-
tary table 3).
Based on the results from table 2, we performed a 
subgroup analysis stratifying patients into antithrom-
botic treatment at the inclusion event (single treatment 
with oral anticoagulation or an antiplatelet agent, or 
dual treatment with oral anticoagulation plus an anti-
platelet agent). The results showed that independent of 
antithrombotic treatment before the gastrointestinal 
bleeding, restarting or modifying treatment to single 
treatment with oral anticoagulation was in general 
associated with the greatest effectiveness and a relative 
safety compared with other restarted treatment strate-
gies and non-resumption of antithrombotic treatment 
(see supplementary table 4).
Concomitant proton pump inhibitor use after 
gastrointestinal bleeding
We carried out a subgroup analysis including patients 
who received concomitant treatment with proton pump 
inhibitors after gastrointestinal bleeding (table 4).
Sensitivity analyses
Supplementary table 2 presents the numbers and risks 
of events within one year of follow-up, and the results 
showed consistency with the main results in table 3. 
Supplementary figure 1 shows cumulative incidences of 
events within five years after the inclusion day.
For the purpose of sensitivity analyses, we changed 
the 90 days blanking period to 30, 60, and 120 days. The 
results based on a shorter or longer blanking period 
supported the main results with the 90 days blanking 
period (table 5).
We carried out four additional sensitivity analyses. 
Firstly, we used unadjusted Cox models. Secondly, we 
adjusted the Cox models for potential confounders 
according to previous gastroscopy, cancer, chronic kid-
ney disease, liver failure, alcohol misuse, and the use of 
non-steroidal anti-inflammatory drugs and dipyrida-
mole 90 days before baseline. Thirdly, we carried out 
analyses with oral anticoagulation separated into vita-
min K antagonists and non-vitamin K antagonist oral 
anticoagulants, and antiplatelets separated into aspirin 
and adenosine diphosphate receptor antagonists. 
Finally, we carried out analyses with follow-up starting 
the day after discharge (without the 90 days blanking 
period), assuming patients continued with the same 
antithrombotic treatment after discharge as before the 
inclusion event, and until they ran out of tablets. Sup-
plementary table 5 shows the results of the sensitivity 
analyses; overall, the results were similar to the main 
results in table 3.
table 4 | Subgroup analysis including patients with additional proton pump inhibitor use with hazard ratios (95% 
confidence intervals) for restart of antithrombotic treatment and associated risk of outcome
outcomes
Single treatment dual treatment
oral 
anticoagulation antiplatelets
oral 
anticoagulation+ 
antiplatelets
aspirin+adenosine 
diphosphate 
receptor antagonist
All cause mortality 0.38 (0.32 to 0.45) 0.75 (0.67 to 0.85) 0.41 (0.31 to 0.53) 0.78 (0.49 to 1.24)
Thromboembolism 0.40 (0.30 to 0.54) 0.75 (0.60 to 0.95) 0.57 (0.37 to 0.87) 0.77 (0.33 to 1.80)
Major bleeding 1.45 (1.10 to 1.91) 1.26 (0.95 to 1.67) 1.50 (1.02 to 2.22) 1.44 (0.57 to 3.67)
Recurrent gastrointestinal bleeding 1.26 (0.85 to 1.87) 1.09 (0.73 to 1.64) 1.30 (0.74 to 2.29) 0.58 (0.08 to 4.36)
table 3 | Main results presenting hazard ratios (95% confidence intervals) for restarting antithrombotic treatment and 
associated risk of outcome
outcomes
no of 
events
Single treatment dual treatment
oral 
anticoagulation antiplatelets
oral 
anticoagulation+ 
antiplatelets
aspirin+adenosine 
diphosphate 
receptor antagonist
All cause mortality 1730 0.39 (0.34 to 0.46) 0.76 (0.68 to 0.86) 0.41 (0.32 to 0.52) 0.88 (0.57 to 1.36)
Thromboembolism 496 0.41 (0.31 to 0.54) 0.76 (0.61 to 0.95) 0.54 (0.36 to 0.82) 0.79 (0.34 to 1.84)
Major bleeding 454 1.37 (1.06 to 1.77) 1.25 (0.96 to 1.62) 1.44 (1.00 to 2.08) 1.36 (0.54 to 3.43)
Recurrent gastrointestinal bleeding 216 1.22 (0.84 to 1.77) 1.19 (0.82 to 1.74) 1.34 (0.79 to 2.28) 0.58 (0.08 to 4.30)
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discussion
In this nationwide study of 4602 patients with non- 
valvular atrial fibrillation who were discharged from 
hospital after a gastrointestinal bleeding event while 
receiving antithrombotic treatment, we found the 
cumulative incidence of death was high; 39.9% within 
two years. Secondly, 27.1% of the patients did not 
resume antithrombotic treatment after the gastrointes-
tinal bleed. Thirdly, among patients surviving the first 
90 days after gastrointestinal bleeding, restarting single 
treatment with oral anticoagulation was associated 
with the lowest risk of all cause mortality and 
 thromboembolism compared with non-resumption of 
antithrombotic treatment. Fourthly, none of the 
restarted antithrombotic treatment regimens was asso-
ciated with a significantly increased risk of recurrent 
gastrointestinal bleeding.
gastrointestinal bleeding as a powerful indicator 
of death
Gastrointestinal bleeding is a serious event with high 
case fatality, and this study supports the results from 
the UK national audit 2007.23  Gastrointestinal bleeding 
is associated with a high mortality, especially among 
elderly patients with atrial fibrillation and multiple 
comorbidities who take antithrombotics, which is in 
accordance with our results and those of other stud-
ies.24 These findings reinforce the importance of gastro-
intestinal bleeding as a powerful indicator of death—that 
is, in our study 39.9% of patients died within two years 
after gastrointestinal bleeding. Stroke prevention 
among these high risk patients is a clinical challenge 
and a multidisciplinary task.
antithrombotic treatment after gastrointestinal 
bleeding
The decision not to resume antithrombotic treatment 
might be made to avoid rebleeding at the expense of 
an increased risk of stroke after gastrointestinal bleed-
ing in patients with atrial fibrillation, and our observa-
tional data showed that 27.1% of patients did not 
resume antithrombotic treatment after gastrointesti-
nal  bleeding. In a comparable retrospective study, 
Qureshi and colleagues9 reported that 50.9% of 
patients with atrial fibrillation did not resume warfa-
rin treatment after gastrointestinal bleeding. In the 
present study it was an option for patients to restart 
single treatment with antiplatelets, and we found that 
a large proportion started this treatment (aspirin 
35.5% and adenosine diphosphate receptor antagonist 
3.0%) with a mean CHA2DS2-VASc score of 3.7 (SD 1.5), 
despite that it has been established that patients with 
atrial fibrillation have the most net-clinical benefit 
from single treatment with oral anticoagulation.1 16 25 26 
This is further supported by our study, which suggests 
that after gastrointestinal bleeding the benefits of 
restarting oral anticoagulation outweigh the risks of 
recurrent bleeding compared with other antithrom-
botic treatment regimens or non-resumption of anti-
thrombotics—that is, single treatment with oral 
table 5 | Sensitivity analyses with hazard ratios (95% confidence intervals) based on 30, 60, or 120 days blanking periods
Blanking periods
outcomes
all cause mortality thromboembolism Major bleeding
recurrent 
gastrointestinal  
bleeding
30 days blanking period*
No of events 2063 581 570 294
Single treatment:
 Oral anticoagulation (n=783) 0.39 (0.34 to 0.45) 0.45 (0.35 to 0.59) 1.31 (1.02 to 1.68) 1.22 (0.86 to 1.72)
 Antiplatelets (n=1814) 0.79 (0.71 to 0.87) 0.80 (0.66 to 0.96) 1.24 (1.00 to 1.55) 1.21 (0.90 to 1.64)
Dual treatment:
 Oral anticoagulation+antiplatelets (n=663) 0.50 (0.41 to 0.61) 0.58 (0.41to 0.83) 1.28 (0.93 to 1.75) 1.13 (0.72 to 1.77)
 Aspirin+adenosine diphosphate receptor antagonists (n=115) 0.74 (0.50 to 1.09) 0.68 (0.32 to 1.48) 2.06 (1.13 to 3.74) 1.88 (0.79 to 4.51)
60 days blanking period†
No of events 1857 532 490 234
Single treatment:
 Oral anticoagulation (n=707) 0.38 (0.33 to 0.45) 0.43 (0.33 to 0.57) 1.40 (1.08 to 1.82) 1.23 (0.84 to 1.78)
 Antiplatelets (n=1575) 0.79 (0.71 to 0.88) 0.79 (0.65 to 0.97) 1.30 (1.03 to 1.64) 1.28 (0.92 to 1.78)
Dual treatment:
 Oral anticoagulation+antiplatelets (n=506) 0.49 (0.40 to 0.61) 0.59 (0.40 to 0.86) 1.47 (1.05 to 2.06) 1.44 (0.89 to 2.33)
 Aspirin+adenosine diphosphate receptor antagonists (n=84) 0.81 (0.53 to 1.22) 0.85 (0.39 to 1.83) 1.52 (0.70 to 3.30) 0.50 (0.07 to 3.60)
120 days blanking period‡
No of events 1414 408 390 177
Single treatment:
 Oral anticoagulation (n=724) 0.36 (0.30 to 0.43) 0.43 (0.31 to 0.58) 1.41 (1.05 to 1.88) 1.17 (0.76 to 1.79)
 Antiplatelets (n=1182) 0.77 (0.69 to 0.87) 0.77 (0.61 to 0.96) 1.37 (1.06 to 1.78) 1.25 (0.86 to 1.83)
Dual treatment:
 Oral anticoagulation+antiplatelets (n=333) 0.44 (0.34 to 0.58) 0.52 (0.33 to 0.81) 1.63 (1.12 to 2.37) 1.48 (0.86 to 2.55)
 Aspirin+adenosine diphosphate receptor antagonists (n=50) 0.76 (0.47 to 1.25) 0.99 (0.43 to 2.28) 1.52 (0.61 to 3.78) 0.66 (0.09 to 4.86)
*Excluded 731 patients during blanking period. 437 patients did not resume treatment, 32 used triple treatment (oral anticoagulation+aspirin+adenosine diphosphate receptor antagonist.
†Excluded 1005 patients during blanking period. 704 patients did not resume treatment, 21 used triple treatment (oral anticoagulation+aspirin+adenosine diphosphate receptor antagonist.
‡Excluded 1338 patients during blanking period. 968 patients did not resume treatment, 7 used triple treatment (oral anticoagulation+aspirin+adenosine diphosphate receptor antagonist.
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anticoagulation reduced mortality. Furthermore, this 
is in agreement with the study by Qureshi and col-
leagues, who reported benefit of restarting warfarin on 
mortality and thromboembolism and without the 
additional cost of recurrent gastrointestinal bleeding.9 
Similarly, Witt and colleagues27  found that after gas-
trointestinal bleeding, restarting warfarin treatment 
compared with no treatment was associated with a 
lower risk of death and thromboembolism without a 
significantly increased risk of recurrent gastrointesti-
nal bleeding. However, this study did not focus solely 
on patients with atrial fibrillation. A randomised con-
trolled trial by Sung and colleagues28 tested continua-
tion of single treatment with aspirin compared with no 
treatment after ulcer related bleeding. Despite the 
study’s small sample size of 156 patients initially 
treated with aspirin as prophylaxis for cardiovascular 
or cerebrovascular diseases, the authors concluded 
that continuing aspirin treatment versus non-resump-
tion potentially reduced mortality but increased the 
risk of recurrent gastrointestinal bleeding. The results 
of our observational study draw a parallel to those of 
that study, that restarting treatment is beneficial and 
outweighs the risks of recurrent bleeding; however, 
our study exclusively included patients with atrial 
fibrillation, and they benefited most from restarting 
single treatment with oral anticoagulation.
In the current study, patients who restarted single 
treatment with antiplatelets or combination treat-
ment had the highest risk scores of stroke and bleed-
ing, as indicated by the CHA2DS2-VASc score and 
HAS-BLED score, respectively. Even though we 
adjusted for these risk scores, confounding by indica-
tion may have influenced our results leading to an 
underestimation of subsequent stroke and an overes-
timation of recurrent bleeding in these treatment 
groups. However, this study came across a surprising 
finding—that patients who restarted single treatment 
with oral anticoagulation and those who did not 
resume antithrombotic treatment had similar risk 
scores for stroke (CHA2DS2-VASc: 3.3 (SD 1.6) and 3.4 
(SD 1.5), respectively) and bleeding (HAS-BLED: 2.6 
(SD 0.9) and 2.6 (SD 0.9), respectively), but during fol-
low-up patients who restarted single treatment with 
oral anticoagulation benefited from a decreased asso-
ciated risk of all cause mortality and thromboembo-
lism without an increased risk of recurrent 
gastrointestinal bleeding. This suggests the need and 
importance of restarting single treatment with oral 
anticoagulation in patients with atrial fibrillation 
after gastrointestinal bleeding.
the blanking period
During the 90 days blanking period, we missed a pro-
portion of events. Moreover, the results could be less 
generalisable in a clinical every day practice, because 
the 90 days blanking period obscured what happened 
in terms of antithrombotic treatment within the first 90 
days after the gastrointestinal bleeding. To evaluate 
the effect of changing the blanking period, we carried 
out sensitivity analyses not including the blanking 
period or changing the blanking period to 30, 60, or 120 
days. The results from the sensitivity analyses sup-
ported the main results based on the 90 days blanking 
period.
use of proton pump inhibitors after gastrointestinal 
bleeding
In international guidelines the use of proton pump 
inhibitors is indicated in patients with a history of gas-
trointestinal bleeding treated with dual antiplatelet 
drugs or concomitant anticoagulation treatment.29 30 In 
this study, the use of proton pump inhibitors after gas-
trointestinal bleeding in the groups who restarted anti-
thrombotic treatment ranged from 90.0% to 96.1% at 
baseline, showing that recommendations are generally 
followed. The results from the subgroup analysis based 
on patients who restarted antithrombotic treatment and 
used concomitant proton pump inhibitors did not devi-
ate much from the main results (table 4).
restart of antithrombotic treatment and recurrent 
bleeding
One of our objectives was to examine major bleeding, 
which to our knowledge has not been examined previ-
ously in the selected study population. In patients 
with atrial fibrillation, combination treatment is asso-
ciated with a higher risk of major bleeding than is sin-
gle treatment.4  Moreover, drug-drug interactions 
between antithrombotics increase the risk of gastroin-
testinal bleeding, and Delaney and colleagues31 con-
cluded that dual treatment with aspirin added to 
warfarin or clopidogrel was associated with a greater 
risk of gastrointestinal bleeding than that observed 
with each drug alone. The present study found that 
single or dual treatment was not significantly associ-
ated with an increased risk of recurrent gastrointesti-
nal bleeding; however, lack of statistical power could 
have influenced this result.
non-vitamin K antagonist oral anticoagulants after 
gastrointestinal bleeding
In the past three or four years, the use of non-vitamin K 
antagonist oral anticoagulants is increasing at the 
expense of vitamin K antagonists,21 but owing to the 
paucity of data on non-vitamin K antagonist oral anti-
coagulants in the current study we cannot conclude 
anything on the efficacy or safety of these drugs in this 
setting. Consideration of the patient’s profile is neces-
sary when balancing the risks of stroke with recurrent 
bleeding after gastrointestinal bleeding in patients with 
atrial fibrillation.
Strengths and limitations of this study
The major strength of the present study was the oppor-
tunity to include a nationwide cohort of 4602 patients 
with atrial fibrillation independent of sex, age, socio-
economic status, or participation in health insurance 
programmes. All Danish residents are covered by a 
public health insurance system, which ensures regis-
tration of all hospital admissions and outpatient con-
tacts. In addition, pharmacies register all claimed 
doi1 02.00;76/bmj.h15876 | BMJ   2015;101h15876 | the bmj
RESEARCH
10
prescriptions, and the Danish registries are well vali-
dated.12 32 33 Aspirin, proton pump inhibitors, non-ste-
roidal anti-inflammatory drugs, and H2 receptor 
antagonists are also available over the counter; how-
ever, owing to a partial reimbursement system in Den-
mark, chronic users mainly claim medicine on 
prescription. In 2012, 92% of all aspirin was sold as a 
prescription drug.34 The time dependent statistical 
models based on all prescriptions claimed added 
strength to the results, but from the registries we were 
not able to determine whether patients took their tab-
lets after the prescription had been dispensed. This 
could have led to a potential overestimation of events 
in the groups who restarted antithrombotic drugs. 
Another limitation was that patients included near the 
end of the study had decreased risk time to develop an 
event. We used the major and non-major diagnosis 
codes of gastrointestinal bleeding to ensure high sensi-
tivity, but no detailed clinical information was avail-
able for any of the events. We were not able to 
distinguish between lower and upper gastrointestinal 
bleeding, owing to lack of power.
The international normalised ratio levels, the quality 
of warfarin control, serum creatinine concentration, 
renal function, haemoglobin levels, and other potential 
confounders with no possibilities for identification in 
the registries, could have influenced our results. We 
attempted to minimise these influences by carrying out 
sensitivity analysis—for example, by adjusting for 
chronic kidney disease and by using methods from pre-
vious parallel studies.4  15  16
The observational study design did not permit defi-
nite causations to be concluded; instead, we examined 
the associations between restart of antithrombotic 
treatment and outcomes. The demand for a randomised 
controlled trial on restarting oral anticoagulation and 
the risk of stroke and recurrent bleeding after a gastro-
intestinal bleeding among patients with atrial fibrilla-
tion is increasing, but such a trial would face many 
challenges.
Conclusion
Mortality was high among patients with atrial fibrilla-
tion who were discharged from hospital after a gastroin-
testinal bleeding event while taking antithrombotics. 
More than a quarter did not resume treatment. How-
ever, among patients surviving the first 90 days after 
gastrointestinal bleeding, restarting single treatment 
with oral anticoagulation was associated with the low-
est risk of all cause mortality and thromboembolism, 
and a relative safe use regarding the risk of recurrent 
bleeding, compared with non-resumption of antithrom-
botic treatment or restarting other antithrombotic treat-
ment regimens.
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